Psoriatic ArthritisPhase 3INVIGORATE 2NCT04209205
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
A Phase 3 study testing AIN457 6 mg/kg i.v. and AIN457 3 mg/kg in people with Psoriatic Arthritis, run by Novartis Pharmaceuticals at 80 sites in 15 countries.
Trial summary
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA)… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Psoriatic Arthritis
- What is being tested?
- AIN457 6 mg/kg i.v. and AIN457 3 mg/kg
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 381 participants
- Where
- 80 sitesin 15 countries
- Study dates
- 29 Jan 2020to 17 May 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Patients eligible for inclusion in this study had to fulfill all of the following criteria:
- Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)
- Rheumatoid factor and anti-CCP antibodies negative at screening
- Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or documented history of plaque psoriasis
- Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization with inadequate control of symptoms or at least one dose if stopped due to intolerance to NSAIDs
- Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or equivalent for at least 2 weeks before randomization and should remain on a stable dose up to Week 16
- Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the dose is stable for at least 4 weeks before randomization and should remain on a stable dose up to Week 52.
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
- Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician
- Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine)
- Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor
- Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, UV therapy) at randomization. The following wash-out periods need to be observed:
- Oral or topical retinoids- 4 weeks
- Photochemotherapy (e.g. PUVA)- 4 weeks
- Phototherapy (UVA or UVB)- 2 weeks
- Topical skin treatments (except in face, eyes, scalp and genital area during screening, only corticosteroids with mild to moderate potency)- 2 weeks
- Any intramuscular or intravenous corticosteroid treatment within 4 weeks before randomization.
- Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before randomization.
- Subjects who have previously been treated with more than 3 different TNF inhibitors (investigational or approved).
- Subjects who have ever received biologic immunomodulating agents, investigational or approved except for those targeting TNFα.
- Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
Trial locations and contacts
80 sites in 15 countries.
80 sites in 15 countries
United States31 sites
Novartis Investigative Site
Austin, Texas, 78731
Novartis Investigative Site
Birmingham, Alabama, 35205
Novartis Investigative Site
Bowling Green, Kentucky, 42101
Novartis Investigative Site
Clearwater, Florida, 33765
Novartis Investigative Site
Denver, Colorado, 80230
Novartis Investigative Site
Duncansville, Pennsylvania, 16635
Novartis Investigative Site
Fountain Valley, California, 92708
Novartis Investigative Site
Fullerton, California, 92835
Novartis Investigative Site
Greensboro, North Carolina, 27408
Novartis Investigative Site
Indianapolis, Indiana, 46256
Novartis Investigative Site
Jackson, Tennessee, 38305
Novartis Investigative Site
La Mesa, California, 91942
Novartis Investigative Site
Lincoln, Nebraska, 68516
Novartis Investigative Site
Marietta, Georgia, 30060
Novartis Investigative Site
Mesquite, Texas, 75150
Novartis Investigative Site
Miami, Florida, 33032
Novartis Investigative Site
Middleburg Heights, Ohio, 44130
Novartis Investigative Site
Newport News, Virginia, 23608
Novartis Investigative Site
Ocoee, Florida, 34761
Novartis Investigative Site
Oklahoma City, Oklahoma, 73103
Novartis Investigative Site
Plantation, Florida, 33324
Novartis Investigative Site
Rochester, New York, 14642
Novartis Investigative Site
Santa Monica, California, 90404
Novartis Investigative Site
St Louis, Missouri, 63117
Novartis Investigative Site
Tampa, Florida, 33624
Novartis Investigative Site
Tulsa, Oklahoma, 74136
Novartis Investigative Site
Upland, California, 91786
Novartis Investigative Site
Van Nuys, California, 91405
Novartis Investigative Site
Voorhees Township, New Jersey, 08043
Novartis Investigative Site
West Hills, California, 91307
Novartis Investigative Site
Winter Park, Florida, 32789
Russia7 sites
Novartis Investigative Site
Kemerovo, 650029
Novartis Investigative Site
Nizhny Novgorod, 603018
Novartis Investigative Site
Rostov-on-Don, 344022
Novartis Investigative Site
Saint Petersburg, 190068
Novartis Investigative Site
Saint Petersburg, 197022
Novartis Investigative Site
Yaroslavl, 150003
Novartis Investigative Site
Yekaterinburg, 620109
Bulgaria5 sites
Novartis Investigative Site
Burgas, 8000
Novartis Investigative Site
Plovdiv, 4000
Novartis Investigative Site
Plovdiv, 4002
Novartis Investigative Site
Sofia, 1413
Novartis Investigative Site
Sofia, 1431
Poland5 sites
Novartis Investigative Site
Karwiany, 52-200
Novartis Investigative Site
Krakow, Lesser Poland Voivodeship, 30-510
Novartis Investigative Site
Krakow, 30 002
Novartis Investigative Site
Sochaczew, 96-500
Novartis Investigative Site
Warsaw, 02-962
Colombia4 sites
Novartis Investigative Site
Barranquilla, Atlántico, 080002
Novartis Investigative Site
Bogotá, 110221
Novartis Investigative Site
Bucaramanga, Santander Department, 0001
Novartis Investigative Site
Cundinamarca, 111121
Czechia4 sites
Novartis Investigative Site
Prague, 128 50
Novartis Investigative Site
Prague, 140 59
Novartis Investigative Site
Prague, 150 06
Novartis Investigative Site
Uherské Hradiště, 686 01
India4 sites
Novartis Investigative Site
Bangalore, Karnataka, 560 079
Novartis Investigative Site
Nashik, Maharashtra, 422 101
Novartis Investigative Site
New Delhi, 110029
Novartis Investigative Site
Surat, Gujarat, 395009
Philippines4 sites
Novartis Investigative Site
Dasmariñas, Cavite, 4114
Novartis Investigative Site
Lipa City, Batangas, 4217
Novartis Investigative Site
Manila, 1008
Novartis Investigative Site
Quezon City, 1102
Thailand4 sites
Novartis Investigative Site
Bangkok, 10400
Novartis Investigative Site
Bangkoknoi, Bangkok, 10700
Novartis Investigative Site
Khon Kaen, THA, 40002
Novartis Investigative Site
Songkhla, Hat Yai, 90110
Malaysia3 sites
Novartis Investigative Site
Kuching, Sarawak, 93586
Novartis Investigative Site
Selangor Darul Ehsan, 68100
Novartis Investigative Site
Seremban, Negeri Sembilan, 70300
Brazil2 sites
Novartis Investigative Site
Salvador, Estado de Bahia, 40150 150
Novartis Investigative Site
São Paulo, São Paulo, 04266 010
Greece2 sites
Novartis Investigative Site
Athens, 12462
Novartis Investigative Site
Thessaloniki, 54622
Guatemala2 sites
Novartis Investigative Site
Guatemala City, 01001
Novartis Investigative Site
Guatemala City, 01010
South Africa2 sites
Novartis Investigative Site
Panorama, Western Cape, 7500
Novartis Investigative Site
Stellenbosch, 7600
Turkey (Türkiye)1 site
Novartis Investigative Site
Bursa, Gorukle, 16059
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.
Read the detailed description
This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design. A screening (SCR) period running up to 10 weeks before randomization was used to assess subject eligibility followed by a treatment period of 52 weeks.
At baseline, 381 patients with active psoriatic arthritis were randomized to one of the two treatment groups in a 1:1 randomization:
Group 1: Approximately 190 patients with active psoriatic arthritis; These patients received secukinumab 6 mg/kg i.v. at BSL, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4.
Group 2: Approximately 190 patients with active psoriatic arthritis; These patients received i.v. placebo at BSL and at Weeks 4, 8, and 12, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 16.
Study consisted of 4 periods: a screening period (up to 10 weeks), treatment period 1 (total duration of 16 weeks) and treatment period 2 (total duration of 36 weeks) followed by a safety follow up period of 8 weeks after the end of treatment visit (i.e., Week 52).
Primary endpoint analysis will be performed with Week 16 data (last patient completing Treatment period 1 (Week 16). Long-term efficacy and safety assessments will be performed up to Week 52.
- Conditions
- Psoriatic Arthritis
- Being tested
- AIN457 6 mg/kg i.v., Placebo, AIN457 3 mg/kg
- Keywords
- Active Psoriatic Arthritis, Intravenous secukinumab, PsA
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AIN457 6 mg/kg i.v.Drug
Also called secukinumab
AIN457 6 mg/kg delivered by i.v. infusion
PlaceboDrug
Matching placebo to AIN457 i.v. infusion
AIN457 3 mg/kgDrug
Also called secukinumab
AIN457 3 mg/kg delivered by i.v. infusion
| Study group | Role | What they receive |
|---|---|---|
| AIN457 6 mg/kg - 3 mg/kg i.v. | Experimental | AIN457 6 mg/kg i.v. infusion at baseline, followed by AIN457 3 mg/kg i.v. infusion every 4 weeks starting at Week 4 through Week 48 (exposure through Week 52). Receives: Drug: AIN457 6 mg/kg i.v.; Drug: AIN457 3 mg/kg |
| Placebo | Placebo comparator | Matching placebo from baseline to Week 16 and switch to AIN457 3mg/kg i.v. infusion every 4 weeks through Week 48 (exposure through Week 52). Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With American College of Rheumatology 50 (ACR50) Response Comparison Between Treatment Groups Using Non-responder Imputation at Week 16 (Full Analysis Set)
Percentage of participants with active psoriatic arthritis (PsA) who achieved an American College of Rheumatology 50 (ACR50) response
The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)
Measured: Baseline up to Week 16
Secondary outcomes (10)
Percentage of Participants With American College of Rheumatology 20 (ACR20) Response Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set)
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-Reactive Protein.
Measured: Baseline up to Week 16
Percentage of Participants With Minimal Disease Activity (MDA 5/7) Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set)
MDA is assessed as 5 of the 7 following: ≤ 1 tender and swollen joint; entheseal count, PASI ≤ 1 or BSA ≤3%, PsA ≤ 15 and disease activity ≤ 20 (VAS) and HAQ-DI© ≤ 0.5
Measured: Baseline up to Week 16
Percentage of Participants With Psoriasis Area and Severity Index 90 (PASi90) Score for Patients With a >= 3% Body Surface Area Psoriasis at Baseline Using On-responder Imputation at Week 16 (Full Analysis Set)
Change from baseline of a 90% reduction in the PASI score for patients with a >= 3% body surface area psoriasis at baseline. Four body surface areas are evaluated (head, trunk and upper and lower limbs) for plaque, erythema, scaling and thickness. The degree of severity of each sign in each of the 4 body areas was assigned a score of 0 to 4. Scores ranged from 0 to 72 and higher scores represent worsening severity.
Measured: Baseline up to Week 16
Psoriatic Arthritis Disease Activity Score (PASDAS) Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
PASDAS is a composite measure developed to assess disease activity in Psoriatic arthritis. It is calculated by utilizing seven measures: Patient reported measures (excluding mental component) (SF-36-PCS), skin, peripheral joint counts (tender and swollen joint counts), dactylitis (LDI), enthesitis (LEI), acute phase response (CRP), and patient and physician global VAS scores. The typical score range is between 0 and 10. Smaller values on PASDAS indicate a better condition; a negative change from baseline indicates improvement.
Measured: Baseline up to Week 16
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.
Measured: Baseline up to Week 16
Short Form 36-Physical Component Summary (SF36-PCS) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
The SF-36 is used to measure health-related quality of life with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Range of scoring is 0 -100, with higher scores indicating better health status.
Measured: Baseline up to Week 16
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
The FACIT-Fatigue is a 13 item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Response scale ranges from 0-4 and the total score range is 0 - 52. Higher scores indicate better quality of life
Measured: Baseline up to Week 16
Modified Nail Psoriasis Severity Index (mNAPSI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
The mNAPSI is an instrument to assess psoriatic nail involvement. Three groups of features (onycholysis and oil-drop dyshromia, pitting and crumbling) were graded on a scale from 0 to 3 for a total subscale of 0 to 9. The next 4 abnormalities (leukonychia, splinter hemorrhages, hyperkeratosis and red spots in the lunula) were graded as absent (0) or present (1) for a total subscale of 0 to 4. The total score was from 0-13 where higher scores represent worse nail disease.
Measured: Baseline up to Week 16
Percentage of Participants With Complete Resolution of Dactylitis at Week 16 Using Non-responder Imputation (Dactylitis Subset)
Dactylitis is characterized by swelling of the entire finger or toe. The Leeds Dactylitis Index (LDI) measures the ratio of the circumference of the affected (swollen) digit. The ratio of circumference is multiplied by a tenderness score, using a modification of LDI that is a binary score (1 for tender, 0 for non-tender). The LDI requires a finger circumference gauge or a dactylometer to measure digital circumference. Scores range from 0 - 20 and lower score indicates better outcome.
Measured: Baseline up to Week 16
Percentage of Participants With Complete Resolution of Enthesitis at Week 16 Using Non-responder Imputation (Enthesitis Subset (LEI))
Enthesitis is inflammation of the enthesis which is where a a tendon or ligament attaches to the bone. The Leeds enthesitis index (LEI) is a validated index that uses 6 sites for evaluation of enthesitis: lateral epicondyle humerus L + R, proximal achilles L + R and medial condyle femur L+R. If enthesitis is present at any of the 6 sites, the subject is counted as a subject with enthesitis.
Measured: Baseline up to Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2019
- Study start29 Jan 2020
- Primary completion17 May 2022
- Study completion17 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 381 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04209205
- Sponsor's protocol ID
- CAIN457P12302
- Acronym
- INVIGORATE 2
- Status last verified
- May 2025
- First submitted
- 30 Oct 2019
- Last updated
- 16 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Publications
Pisal DS, Li Y, Golding A, Nair R, Nikolov NP, Madabushi R, Zhu H, Doddapaneni S, Sahajwalla C, Bi Y, Chen J. Model-Informed Drug Development-Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non-Radiographic Axial Spondyloarthritis. Clin Pharmacol Ther. 2025 Feb;117(2):475-484. doi: 10.1002/cpt.3464. Epub 2024 Oct 16.
PubMed 39411974Kivitz A, Sedova L, Churchill M, Kotha R, Singhal A, Torres A, Valenzuela G, Whelan S, Dumortier T, Zhu X, Martin R, Pricop L. Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study. Arthritis Rheumatol. 2025 Feb;77(2):171-179. doi: 10.1002/art.42997. Epub 2024 Oct 17.
PubMed 39300596
Study at a glance
From the registry record, last updated by the sponsor on 16 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis
- ClinicalTrials.gov ID
- NCT04209205
- Acronym / sponsor ID
- INVIGORATE 2 / CAIN457P12302
- Conditions
- Psoriatic Arthritis
- Keywords
- Active Psoriatic Arthritis, Intravenous secukinumab, PsA
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 381 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 29 Jan 2020 (actual)
- Primary completion
- 17 May 2022 (actual)
- Study completion
- 17 May 2022 (actual)
- First posted
- 24 Dec 2019 (actual)
- Results
- Posted 26 Apr 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous Non-steroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs) and/or anti-tumor necrosis factor (TNF) therapy.
Detailed description
This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design. A screening (SCR) period running up to 10 weeks before randomization was used to assess subject eligibility followed by a treatment period of 52 weeks.
At baseline, 381 patients with active psoriatic arthritis were randomized to one of the two treatment groups in a 1:1 randomization:
Group 1: Approximately 190 patients with active psoriatic arthritis; These patients received secukinumab 6 mg/kg i.v. at BSL, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4.
Group 2: Approximately 190 patients with active psoriatic arthritis; These patients received i.v. placebo at BSL and at Weeks 4, 8, and 12, followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 16.
Study consisted of 4 periods: a screening period (up to 10 weeks), treatment period 1 (total duration of 16 weeks) and treatment period 2 (total duration of 36 weeks) followed by a safety follow up period of 8 weeks after the end of treatment visit (i.e., Week 52).
Primary endpoint analysis will be performed with Week 16 data (last patient completing Treatment period 1 (Week 16). Long-term efficacy and safety assessments will be performed up to Week 52.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AIN457 6 mg/kg - 3 mg/kg i.v. | Experimental | Drug: AIN457 6 mg/kg i.v., Drug: AIN457 3 mg/kgAIN457 6 mg/kg i.v. infusion at baseline, followed by AIN457 3 mg/kg i.v. infusion every 4 weeks starting at Week 4 through Week 48 (exposure through Week 52). |
| Placebo | Placebo comparator | Drug: PlaceboMatching placebo from baseline to Week 16 and switch to AIN457 3mg/kg i.v. infusion every 4 weeks through Week 48 (exposure through Week 52). |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AIN457 6 mg/kg i.v.Also: secukinumabAIN457 6 mg/kg delivered by i.v. infusion | Drug | AIN457 6 mg/kg - 3 mg/kg i.v. |
| PlaceboMatching placebo to AIN457 i.v. infusion | Drug | Placebo |
| AIN457 3 mg/kgAlso: secukinumabAIN457 3 mg/kg delivered by i.v. infusion | Drug | AIN457 6 mg/kg - 3 mg/kg i.v. |
Primary outcome
Percentage of Participants With American College of Rheumatology 50 (ACR50) Response Comparison Between Treatment Groups Using Non-responder Imputation at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Percentage of participants with active psoriatic arthritis (PsA) who achieved an American College of Rheumatology 50 (ACR50) response The ACR50 is a composite measure defined as both improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP)
10 secondary outcomes
Percentage of Participants With American College of Rheumatology 20 (ACR20) Response Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Percentage of Participants With Minimal Disease Activity (MDA 5/7) Comparison Between Treatment Groups Using On-responder Imputation at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Percentage of Participants With Psoriasis Area and Severity Index 90 (PASi90) Score for Patients With a >= 3% Body Surface Area Psoriasis at Baseline Using On-responder Imputation at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Psoriatic Arthritis Disease Activity Score (PASDAS) Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Short Form 36-Physical Component Summary (SF36-PCS) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Modified Nail Psoriasis Severity Index (mNAPSI) Score Change From Baseline Using Mixed Model Repeated Measures (MMRM) at Week 16 (Full Analysis Set)
Time frame: Baseline up to Week 16
Percentage of Participants With Complete Resolution of Dactylitis at Week 16 Using Non-responder Imputation (Dactylitis Subset)
Time frame: Baseline up to Week 16
Percentage of Participants With Complete Resolution of Enthesitis at Week 16 Using Non-responder Imputation (Enthesitis Subset (LEI))
Time frame: Baseline up to Week 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 39411974Pisal DS, Li Y, Golding A, Nair R, Nikolov NP, Madabushi R, Zhu H, Doddapaneni S, Sahajwalla C, Bi Y, Chen J. Model-Informed Drug Development-Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non-Radiographic Axial Spondyloarthritis. Clin Pharmacol Ther. 2025 Feb;117(2):475-484. doi: 10.1002/cpt.3464. Epub 2024 Oct 16.
- Derived from this study: PubMed 39300596Kivitz A, Sedova L, Churchill M, Kotha R, Singhal A, Torres A, Valenzuela G, Whelan S, Dumortier T, Zhu X, Martin R, Pricop L. Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study. Arthritis Rheumatol. 2025 Feb;77(2):171-179. doi: 10.1002/art.42997. Epub 2024 Oct 17.
- A Plain Language Trial Summary is available on www.novctrd.comLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for Psoriatic Arthritis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
80 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing AIN457 6 mg/kg i.v. and AIN457 3 mg/kg in people with Psoriatic Arthritis, run by Novartis Pharmaceuticals at 80 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 80 sites in United States, Russia, Bulgaria, Poland, Colombia and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Apr 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With American College of Rheumatology 50 (ACR50) Response Comparison Between Treatment Groups Using Non-responder Imputation at Week 16 (Full Analysis Set) (time frame: Baseline up to Week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04209205, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2025.